Autoimmune diseases: discovery of central building block in immune cells

Autoimmune diseases are triggered when the immune system malfunctions and attacks the body's own structures. Although there is not, as yet, any cure for such diseases, their progression can be slowed down by therapeutic measures. Researchers at MedUni Vienna's Center for Physiology and Pharmacology have now discovered a central signaling pathway in immune cells that may help in the development of a new therapeutic approach. Their study was recently published in the journal Cell Reports.

The immune system protects the body from infections of all kinds and is designed to distinguish between foreign threats and the body's own tissues. T cells, which are deployed at the command of other immune cells, the dendritic cells, are an important component of the immune system. The dendritic cells are not only responsible for activating the T cells but also for deactivating them - primarily to prevent them from attacking the body's own tissues. This mechanism, known as immunotolerance, is the key to the current treatments for autoimmune diseases, whereby certain pharmaceutical agents (JAK inhibitors) are used. The aim is to inhibit T-cell activity against endogenous structures, so as to slow down the progression of the autoimmune disease.

JAK inhibitors are used to treat various autoimmune diseases, such as rheumatoid arthritis. The effect of the inhibitors - on all immune cells simultaneously - has been demonstrated in several studies. A research team led by Gernot Schabbauer and Omar Sharif from the Institute of Vascular Biology and Thrombosis Research at MedUni Vienna's Center for Physiology and Pharmacology has now investigated the specific effect of JAK inhibitors on dendritic cells and, in particular, the role played by the immunotolerance of T cells (peripheral T cell tolerogenesis) in autoimmune diseases.

Targeted cell-based therapy

Working in collaboration with scientists at the Christian Doppler Laboratory for Arginine Metabolism in Rheumatoid Arthritis and Multiple Sclerosis at MedUni Vienna and St. Anna Children's Cancer Research, they discovered a key building block in immune cells that is relevant in the context of autoimmune diseases. "This is the signaling pathway in dendritic cells that promotes T-cell tolerogenesis. This enables the dendritic cells to increase the immunotolerance of the T cells in particular and prevent them from attacking the body's own structures," explains the study's lead author Andrea Vogel from MedUni Vienna's Institute of Vascular Biology and Thrombosis Research.

The researchers' findings are a step towards a potential new cell-based therapeutic approach for autoimmune diseases. The aim is to specifically target the signaling pathway in the dendritic cells, so as to "switch off" the misdirected T cells and slow down progression of the autoimmune disease. Further research on this will follow, emphasises Andrea Vogel: "The next thing we want to investigate is whether this signaling pathway in dendritic cells also plays a role in cancer."

Andrea Voge, Katharina Martin, Klara Soukup, Angela Halfmann, Martina Kerndl, Julia S Brunner, Melanie Hofmann, Laura Oberbichler, Ana Korosec, Mario Kuttke, Hannes Datler, Markus Kieler, Laszlo Musiejovsky, Alexander Dohnal, Omar Sharif, Gernot Schabbauer.
JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction.
Cell Reports, 2022. doi: 10.1016/j.celrep.2022.110420

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...